Ursodiol Dosage and Administration for Liver Disease Treatment

Dosage Recommendations by Condition

The European Association for the Study of the Liver recommends 13-15 mg/kg/day for primary biliary cirrhosis, while higher doses of 20-25 mg/kg/day may be considered for primary sclerosing cholangitis, though evidence for efficacy is mixed and high doses may be harmful in late-stage disease 1, 2
Higher doses of 20-25 mg/kg/day demonstrated improvements in liver fibrosis histology and cholangiographic appearances in patients with primary sclerosing cholangitis 1, 2
Very high doses (28-30 mg/kg/day) showed potential harm in late-stage primary sclerosing cholangitis, with increased risk of reaching endpoints such as liver transplantation or development of varices 1, 2
The American Association for the Study of Liver Diseases does not support routine use of UDCA in adult primary sclerosing cholangitis patients 3

Long-term therapy with Ursodiol is generally required for chronic liver diseases, according to the European Association for the Study of the Liver 1
If taking Ursodiol with other medications, maintain appropriate timing between doses to prevent potential interaction with absorption of other medications, as recommended by the American College of Gastroenterology 4

High-dose UDCA (28-30 mg/kg/day) may be harmful in late-stage primary sclerosing cholangitis, as reported by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases 1, 3

In patients with primary sclerosing cholangitis and ulcerative colitis, UDCA may have a role in reducing the risk of colonic dysplasia, though evidence is limited, according to the European Association for the Study of the Liver 1